-
Is maintenance therapy warranted for recurrent mania in a woman with a positive family history of Huntington's disease? Bipolar Disord. (IF 5.4) Pub Date : 2024-03-14 Amarins Gaastra, Erik van Duijn, Annemiek Dols
1 CASE PRESENTATION A 63-year-old woman visited our outpatient clinic 2 months after being involuntarily admitted for a manic psychotic episode. She had been convinced that a bomb would hit her home and that she could talk to angels. When she was admitted, she was initially reluctant to take medication, but she quickly recovered with 10 mg of olanzapine per day and she was discharged after 3 weeks
-
-
Antidepressant monotherapy in treatment‐refractory bipolar II depression Bipolar Disord. (IF 5.4) Pub Date : 2024-03-14 Takeshi Terao
CONFLICT OF INTEREST STATEMENT Interests from the past 3 years are as follows. Dr. Terao received speaker's honoraria from Sumitomo Pharma, Shionogi, Otsuka, Eisai, Daiichi Sankyo, Janssen, Viatris, Takeda, Meiji, Mochida, MSD, and Tanabe-Mitsubishi (Yoshitomi).
-
Advancing clinical practice and discovery research through revised taxonomy: Case in point bipolar disorder diagnosis Bipolar Disord. (IF 5.4) Pub Date : 2024-03-08 Anne Duffy, Paul Grof
In the well-articulated paper by Malhi et al.1 in this journal, several problems with diagnosing bipolar disorder in children are discussed and as rightly pointed out “impede our ability to conduct meaningful research and advance clinical practice”. In fact, one could argue that the diagnostic challenges outlined apply to the diagnoses of mood disorders more generally. That is, reliance on a diagnostic
-
Efficacy and safety of established and off‐label ADHD drug therapies for cognitive impairment or attention‐deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force Bipolar Disord. (IF 5.4) Pub Date : 2024-03-04 Kamilla W. Miskowiak, Zacharias K. Obel, Riccardo Gugliemo, Caterina del Mar Bonnin, Christopher R. Bowie, Vicente Balanzá‐Martínez, Katherine E. Burdick, Andre F. Carvalho, Annemieke Dols, Katie Douglas, Peter Gallagher, Lars V. Kessing, Beny Lafer, Kathryn E. Lewandowski, Carlos López‐Jaramillo, Anabel Martinez‐Aran, Roger S. McIntyre, Richard J. Porter, Scot E. Purdon, Ayal Schaffer, Paul R. A.
BackgroundAbnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (BD) and attention‐deficit hyperactivity disorder (ADHD). This systematic review by the ISBD Targeting Cognition Task Force therefore aimed to investigate the possible benefits on cognition and/or ADHD symptoms and safety of established and off‐label ADHD therapies in BD.MethodsWe
-
Experts by lived experience: Enhancing the patient-provider relationship through patient stories Bipolar Disord. (IF 5.4) Pub Date : 2024-02-21 Tammy Hua, Gregg Martin, Alex Leow
CONFLICT OF INTEREST STATEMENT AL is a cofounder of KeyWise AI and has served as a medical and/or scientific advisor for Otsuka, USA and Buoy Health. All other authors have no conflicts of interest to declare.
-
Metabolomic biomarkers for (R, S)-ketamine and (S)-ketamine in treatment-resistant depression and healthy controls: A systematic review Bipolar Disord. (IF 5.4) Pub Date : 2024-02-07 Rakesh Kumar, Nicolas A. Nuñez, Neha Joshi, Boney Joseph, Alessandra Verde, Ashok Seshadri, Alfredo B. Cuellar Barboza, Larry J. Prokop, Gustavo C. Medeiros, Balwinder Singh
Ketamine is increasingly used for treatment-resistant depression (TRD) while its mechanism of action is still being investigated. In this systematic review, we appraise the current evidence of metabolomic biomarkers for racemic ketamine and esketamine in patients with TRD and healthy controls (HCs).
-
Late-onset delirious mania: Does it ring a bell? Bipolar Disord. (IF 5.4) Pub Date : 2024-02-06 Maria Aa Hansen, Robert Bering, Anders Spanggård, Pedro Barata
Bell's mania was first described in 1849, and other terms have been used to describe this condition, including delirious mania, mania with delirium, and excited delirium. However, no international diagnostic manual has included mania as an independent diagnostic tool. The criteria for delirious mania were proposed by Bond et al.
-
Anhedonia in bipolar depression treated with ketamine Bipolar Disord. (IF 5.4) Pub Date : 2024-02-04 Alina Wilkowska, Mariusz S. Wiglusz, Aleksandra Arciszewska-Leszczuk, Maria Gałuszko-Węgielnik, Wiesław J. Cubała
Bipolar depression is the major cause of morbidity in patients with bipolar disorder. It affects psychosocial functioning and markedly impairs occupational productivity. Anhedonia is one of the most debilitating symptoms of depression contributing to treatment resistance. It correlates with suicidality, low quality of life, social withdrawal, and poor treatment response. Currently, there is no approved
-
Is peripartum anhedonia a missing target? Bipolar Disord. (IF 5.4) Pub Date : 2024-02-01 Marianna Mazza, Giuseppe Marano
The perinatal period is an extremely delicate phase that can involve a high risk for onset of depressive disorders. The Edinburgh Postnatal Depression Scale (EPDS) is a widely validated instrument for assessing perinatal depressive symptoms, including the dimension of anhedonia. There are studies suggesting that the neural mechanism underlying the occurrence of anhedonia in patients with major depressive
-
Correction to “Supercharging collaboration for bipolar research—Breakthrough discoveries for thriving with bipolar disorder (BD2)” Bipolar Disord. (IF 5.4) Pub Date : 2024-01-29
C. M. Altimus, E. G. Baxi, M. A. Frye, E. J. Nestler, D. L. Pham, K. E. Burdick (2023) Supercharging collaboration for bipolar research—Breakthrough discoveries for thriving with bipolar disorder (BD2). Bipolar Disorders, 25, 619–623. The below Funding Statement was not included when the above article originally published and has been now added to the article. Funding related to this publication was
-
Fostering networking opportunities and creating a community of early and mid-career clinicians and researchers within the International Society for Bipolar Disorders Bipolar Disord. (IF 5.4) Pub Date : 2024-02-01 Fabiano A. Gomes, Rebekah S. Huber, Sarah H. Sperry, Tamsyn E. Van Rheenen
The International Society for Bipolar Disorders (ISBD) recognizes that empowering the next generation of professionals focused on bipolar disorder is critical for both the scientific progress of the discipline but also its survival as an organization. The Early and Mid-Career Committee (EMCC) was established to provide a platform from which the ISBD could nurture and support the career development
-
Occurrence of postpartum manic or mixed episodes in women with bipolar I disorder: A systematic review and meta-analysis Bipolar Disord. (IF 5.4) Pub Date : 2024-01-23 Verinder Sharma, Katelyn N. Wood, Bruce Weaver, Dwight Mazmanian, Michael Thomson
Accurate information on the frequency and prevalence of manic or mixed episodes is important for therapeutic, prognostic, and safety concerns. We aimed to estimate the risk of relapse of manic and mixed episodes after delivery in women with bipolar I disorder or schizoaffective disorder—bipolar type.
-
Valproate-induced hyperammonemia, neuroleptic sensitivity, and cerebellar atrophy—A clinical conundrum in the management of bipolar disorder Bipolar Disord. (IF 5.4) Pub Date : 2024-01-22 Samarth S. Shetty, Harshitha H. AnnajiGowda, Ajit Bhalchandra Dahale
Treatment of bipolar disorder (BD) involves complexities especially when patients come with significant sensitivity to various psychotropic medications and comorbidities. The following cases aim to recapitulate and discuss some of such situations.
-
Myelinolysis cases presenting with manic attack after rapid correction of hyponatremia: Two cases Bipolar Disord. (IF 5.4) Pub Date : 2024-01-18 Muhammed Emin Boylu, İsmet Kırpınar
Myelinolysis is a neurological condition that can display diverse psychiatric symptoms, with electrolyte imbalance, alcoholism and malnutrition being the frequent causes. Rapid correction of hyponatremia may trigger pontine and extra-pontine myelinolysis.
-
Comment on published article “A chat about bipolar disorder” Bipolar Disord. (IF 5.4) Pub Date : 2024-01-18 Hinpetch Daungsupawong, Viroj Wiwanitkit
To the Editor, we follow the topic “A chat about bipolar disorder1”. According to the study's findings, ChatGPT proved its ability to deliver basic and informative information on bipolar disorders.
-
Supercharging collaboration for bipolar research—Breakthrough discoveries for thriving with bipolar disorder (BD2) Bipolar Disord. (IF 5.4) Pub Date : 2023-12-21 C. M. Altimus, E. G. Baxi, M. A. Frye, E. J. Nestler, D. L. Pham, K. E. Burdick
CONFLICT OF INTEREST STATEMENT CMA, EGB, EJN, and DLP have nothing to disclose. MAF receives grant support from Assurex Health; honoraria from Carnot Laboratories and American Physician Institute; and has a financial interest in Chymia LLC. KEB receives honoraria from Merck.
-
Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment-resistant schizoaffective disorder Bipolar Disord. (IF 5.4) Pub Date : 2023-12-14 Jin-jie Xu, Chunfeng Xiao, Yanli Pan, Yi-lang Tang, Mingwan Wang, Sheng Li, Gaoming Xie, Jing Du, Yanping Ren, Wei Wang
We report the case of a Chinese male with schizoaffective disorder, an active smoker and a nonresponder to clozapine (600 mg daily). Therapeutic clozapine monitoring was analyzed, revealing a low concentration-dose ratio. A pharmacogenetic test showed that the patient had the CYP1A2*1F/*1F genotype, indicating an ultra-rapid clozapine metabolizer. In combination with fluvoxamine, a CYP1A2 enzyme inhibitor
-
Breaking tradition: A case report on successfully treating psoriasis in a patient with bipolar disorders using biologics, without discontinuing lithium Bipolar Disord. (IF 5.4) Pub Date : 2023-12-06 Francesco Cuniberti, Simone Ribero, Michela Ortoncelli, Cecilia Avetta, Paolo Leombruni, Francesco Oliva
CONFLICT OF INTEREST STATEMENT The authors have no conflict of interest to declare.
-
Aversive agents: Think twice. A case report on disulfiram-induced mania Bipolar Disord. (IF 5.4) Pub Date : 2023-11-27 María Fernanda González-Romero, José María Martínez-Ávila, Elizabeth Moloney, Ignacio García-Cabeza
We present a case of disulfiram-induced mania in a patient with both alcohol use disorder (AUD) and psychostimulant use disorder (PUD), without a history of psychosis or mania. This acute presentation may be linked to the increased dopamine levels caused by disulfiram metabolism. Our patient developed manic symptoms 10 days after starting disulfiram, prescribed to treat the AUD. It should be noted
-
History of the International Society for Bipolar Disorders: 30 years and counting Bipolar Disord. (IF 5.4) Pub Date : 2023-11-23 Holly A. Swartz, Chad Daversa, Ellen Frank
CONFLICT OF INTEREST STATEMENT Dr. Swartz has served as a consultant for Intracellular Therapies, Medscape/WebMD, Physicians Postgraduate Press, Clinical Education Alliance, and Mediflix. She receives royalties from American Psychiatric Association Publishing and Wolters Kluwer (UpToDate). Dr. Frank is an employee of Health Rhythms, Inc. and holds equity in Health Rhythms, Inc. and Adaptive Testing
-
Maternal early pregnancy body mass index and bipolar disorder in the offspring Bipolar Disord. (IF 5.4) Pub Date : 2023-11-20 Rachael J. Beer, Sven Cnattingius, Ezra S. Susser, Lu Wang, Eduardo Villamor
To investigate the association between maternal early pregnancy body mass index (BMI) and offspring bipolar disorder (BPD).
-
From knowledge gaps to career opportunities: The early- to Mid-Career Committee's impact on increasing resources for bipolar disorder professionals Bipolar Disord. (IF 5.4) Pub Date : 2023-11-20 Joanna Jiménez-Pavón, Olivia M. Dean, Georgina M. Hosang, Katie M. Douglas, Rebekah S. Huber, Rachel H. B. Mitchell
CONFLICT OF INTEREST STATEMENT JJP acknowledges financial support from the CONAHCYT's National System of Researchers (SNI) of Mexico. RHBM acknowledges salary support from Academic Scholar Awards from the Department of Psychiatry at the University of Toronto and Sunnybrook Health Sciences Centre and an honourarium from Medscape. OMD has received grant support from the Brain and Behavior Foundation
-
Shifting from prevention of the next episode to optimizing inter-episodic functioning Commentary on “The neuroprogression hypothesis in bipolar disorders: Time for apologies?” Bipolar Disord. (IF 5.4) Pub Date : 2023-11-20 Annemiek Dols, Sigfried Schouws, Melis Orhan, Alexandra Beunders
The question in science is: at what point is there enough evidence to shift paradigm? Strejilevich and colleagues argue in their editorial that the time is here for bipolar disorder (BD).1 The authors argue that we have not been able to prove neuroprogression in BD and that holding on to it will harm patients. A (hyper)focus on prevention of new episodes in BD may lead to overprescribing medication
-
Unmasking bipolarity in recurrent depressive disorder following herpes simplex virus triggered n-methyl-D-aspartate encephalitis Bipolar Disord. (IF 5.4) Pub Date : 2023-11-16 Karthik Narasimhappa, Harkishan Mamtani, Kshiteeja Jain, Vikram V. Holla, Sundarnag Ganjekar, Netravathi Manjunath, Karthik Kulanthaivelu, Geetha Desai
Herpes simplex virus (HSV) infection triggered n-methyl-D-aspartate (NMDA) encephalitis can lead to varied neuropsychiatric manifestations, including movement disorders and manic symptoms. HSV is known to affect the same brain regions as in secondary mania.
-
Processing speed and sustained attention in bipolar disorder and major depressive disorder: A systematic review and meta-analysis Bipolar Disord. (IF 5.4) Pub Date : 2023-11-16 Bethany Little, Megan Anwyll, Laura Norsworthy, Luke Corbett, Mia Schultz-Froggatt, Peter Gallagher
Cognitive impairment is a core feature of bipolar disorder (BD) and major depressive disorder (MDD). Deficits in processing speed (PS) and sustained attention (SA) may be particularly impaired and may underpin a broader profile of deficits, however current knowledge of the nature of these impairments is limited by heterogeneous results in the literature. Few reviews to date have attempted to disentangle
-
Concurrent lithium and haemodialysis treatment: Clinical recommendations based on the literature and a multicentre survey Bipolar Disord. (IF 5.4) Pub Date : 2023-11-15 Wytse J. Kuiper, Koen P. Grootens, Angèle P. M. Kerckhoffs
Lithium has an irreplaceable role in the treatment of severe mood disorders, but declining renal function associated with its use leads to clinical dilemmas. Although not often applied, and requiring close monitoring and multidisciplinary actions, concurrent lithium and haemodialysis treatment (CLHT) is a feasible option. To our knowledge, however, there are no detailed consensus- or evidence-based
-
Is intravenous valproate more efficacious than oral valproate for inpatients with bipolar I disorder with a manic or depressive episode and concomitant symptoms of opposite polarity? Bipolar Disord. (IF 5.4) Pub Date : 2023-11-13 Alessandro Cuomo, Giovanni Barillà, Matteo Cattolico, Pietro Carmellini, Alessandro Spiti, Andrea Pozza, Andrea Fagiolini
Valproic acid (VPA) is a commonly prescribed mood stabilizer, available in both oral (OS) and intravenous (IV) formulations. However, few studies have compared their safety and efficacy. This retrospective study aimed to investigate the safety and efficacy of and IV-VPA in patients with Bipolar Disorder.
-
Heterogeneity in the longitudinal courses of global functioning in children at familial risk of major psychiatric disorders: Association with trauma and familial characteristics Bipolar Disord. (IF 5.4) Pub Date : 2023-11-13 Alexandre Bureau, Nicolas Berthelot, Jasmin Ricard, Camille Lafrance, Valérie Jomphe, Abdoulaye Dioni, Énora Fortin-Fabbro, Marie-Claude Boisvert, Michel Maziade
The extent to which heterogeneity in childhood risk trajectories may underlie later heterogeneity in schizophrenia (SZ), bipolar disorder (BP), and major depressive disorder (MDD) remains a chief question. Answers may optimally be found by studying the longitudinal trajectories of children born to an affected parent. We aimed to differentiate trajectories of global functioning and their sensitive periods
-
Challenges in defining treatment-resistant mania in adults: A systematic review Bipolar Disord. (IF 5.4) Pub Date : 2023-11-14 Christina Gonzalez-Torres, Benoit H. Mulsant, M. Ishrat Husain, Martin Alda, Robert C. Young, Abigail Ortiz
To review the definitions of treatment-resistant mania (TRM) in the literature and propose criteria for an operationalized definition.
-
Letter to editor: Bipolar disorders Bipolar Disord. (IF 5.4) Pub Date : 2023-11-07 Robert H. Belmaker
It was surprising to read the editorial by Malhi and Bauer1 in the last issue of bipolar disorders entitled “Lithium First: Not Merely First Line.” I was unsure of the reason for the authors' triumphalist tone, since all the references were well known and nothing new. I have spent a large part of my 50-year research and clinical psychopharmacology career studying lithium biochemically and in animal
-
Use of botulinum toxin A for depression symptoms in patients with treatment-resistant bipolar illness: A case series Bipolar Disord. (IF 5.4) Pub Date : 2023-11-05 Ali A. Farooqui, Jessica M. Fulkerson, Rif S. El-Mallakh
CONFLICT OF INTEREST STATEMENT Dr. El-Mallakh has research funding from Sunovion and is on the speakers' bureau of Axsome, Intracellular, Janssen, Lundbeck, Myriad, Noven, Otsuka, and Teva. Dr. Farooqui is on the speaker's bureau of Abbvie and BioXcel.
-
Bipolar disorder assessment and monitoring measures in clinical care: Updates from a large randomized controlled trial in primary care Bipolar Disord. (IF 5.4) Pub Date : 2023-11-03 Joseph M. Cerimele, John C. Fortney
CONFLICT OF INTEREST STATEMENT The authors report no conflicts of interest.
-
Disulfiram-induced mania: A case report Bipolar Disord. (IF 5.4) Pub Date : 2023-11-02 Jessica Batten, Vijay Gorrepati, Tawny Smith, David Spelber, Jorge Almeida
CONFLICT OF INTEREST STATEMENT The authors of this article have no conflict of interest to disclose.
-
Demographic and clinical associations to employment status in older-age bipolar disorder: Analysis from the GAGE-BD database project Bipolar Disord. (IF 5.4) Pub Date : 2023-10-05 Amulya Mallu, Carol K. Chan, Lisa T. Eyler, Annemiek Dols, Soham Rej, Hilary P. Blumberg, Kaylee Sarna, Brent P. Forester, Regan E. Patrick, Orestes V. Forlenza, Esther Jimenez, Eduard Vieta, Sigfried Schouws, Ashley Sutherland, Joy Yala, Farren B. S. Briggs, Martha Sajatovic
The current literature on employment in older adults with bipolar disorder (OABD) is limited. Using the Global Aging and Geriatric Experiments in Bipolar Disorder Database (GAGE-BD), we examined the relationship of occupational status in OABD to other demographic and clinical characteristics.
-
A chat about bipolar disorder Bipolar Disord. (IF 5.4) Pub Date : 2023-09-28 Gordon Parker, Michael J. Spoelma
This study aimed to assess the capabilities of ChatGPT (Chat Generative Pre-Trained Transformer) in generating informative content related to bipolar disorders. The objectives were to evaluate its ability to provide accurate information on symptoms, classification, causes, and management of bipolar disorder and to explore its creativity in generating topic-related songs.
-
Multi-trial, aggregated, individual participant data mega-analysis of short-term antidepressant versus mood stabilizer monotherapy of bipolar type II major depressive episode Bipolar Disord. (IF 5.4) Pub Date : 2023-09-25 Jay D. Amsterdam, Colin Xu
Few studies have systematically examined the safety and effectiveness of antidepressant versus mood stabilizer monotherapy of bipolar II depression. To date, there are no aggregated or mega-analyses of prospective trials of individual participant-level data (IPD) to inform future treatment guidelines on the relative safety and effectiveness of antidepressant or lithium monotherapy.
-
Dark skies before the storm: The Chronos syndrome Bipolar Disord. (IF 5.4) Pub Date : 2023-09-25 Pierre A. Geoffroy
Dear Editor, Bipolar disorders recently published an intriguing study indicating that 6.1% of individuals with subthreshold manic symptoms progressed to a full-blown hypomanic or manic episode during a 3-year follow-up.1 The study also identified 11 risk factors associated with this unfavorable course, with the most significant ones being a history of depression or dysthymia, living without a partner
-
Erratum Bipolar Disord. (IF 5.4) Pub Date : 2023-09-19
In the article by Montejo et al.,1 the following sentence was missed in the Acknowledgments section: “Projects PI17/01066 and PI20/00344, funded by the Instituto de Salud Carlos III and cofunded by the European Union (FEDER) (“Una manera de hacer Europa”).” We apologize for this oversight.
-
Low and very low lithium levels: Thyroid effects are small but still require monitoring Bipolar Disord. (IF 5.4) Pub Date : 2023-09-13 James Phelps, Olivia Pipitone Coskey
Low doses of lithium, as might be used for mood or dementia prevention, do not carry the same renal, toxicity, and tolerability problems of doses used for prophylaxis or treatment of mania. However, thyroid effects of low doses have not been investigated. Our goal in this study was to assess the changes in thyroid-stimulating hormone (TSH) associated with a broad range of lithium levels, including
-
“The neuroprogression hypothesis in bipolar disorders: Time for apologies?” Bipolar Disord. (IF 5.4) Pub Date : 2023-08-14 Sergio A. Strejilevich, Cecilia Samamé, Danilo Quiroz
CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest.
-
Esketamine nasal spray in severe bipolar depression with borderline personality disorder and history of multiple substance abuse: A case report Bipolar Disord. (IF 5.4) Pub Date : 2023-08-10 Renato de Filippis, Pasquale De Fazio
CONFLICT OF INTEREST STATEMENT Renato de Filippis received travel grants and/or speaker/consultant fees from Janssen-Cilag. Pasquale De Fazio declares that the research was conducted without any commercial or financial relationship that could be construed as a potential conflict of interest.
-
Sleep patterns among preschool offspring of parents with and without psychopathology: Association with the development of psychopathology in childhood Bipolar Disord. (IF 5.4) Pub Date : 2023-08-09 Jessica C. Levenson, Heather M. Joseph, John Merranko, Danella M. Hafeman, Kelly Monk, Benjamin I. Goldstein, David Axelson, Dara Sakolsky, Rasim S. Diler, Tina Goldstein, Boris Birmaher
Disturbed sleep during early childhood predicts social–emotional problems. However, it is not known how various early childhood sleep phenotypes are associated with the development of childhood psychopathology, nor whether these relationships vary as a function of parental psychopathology. We identified sleep phenotypes among preschool youth; examined whether these phenotypes were associated with child
-
Obsessive–compulsive disorder as the onset of bipolar disorder in adolescence Bipolar Disord. (IF 5.4) Pub Date : 2023-08-09 Ester di Giacomo, Federica Moretti, Fabrizia Colmegna, Massimo Clerici
The onset of bipolar disorder (BD) usually occurs during adolescence or early adulthood. Several studies show an alarming duration of untreated illness (5 years) with 60% of people with BD reporting 1–4 different diagnoses before that of BD, with consequent treatment delay. In recent years, a growing interest in preliminary phases of BD or sub-syndromic signs has been reported. Obsessive–compulsive
-
Lithium and long-term renal effects: A complex clinical concern Bipolar Disord. (IF 5.4) Pub Date : 2023-08-08 Michael Gitlin
Potential nephrotoxicity from long-term lithium use has been well documented for many decades, with the first paper demonstrating structural renal damage, primarily in the form of interstitial nephritis (with scarring of the interstitium, tubular destruction and relative preservation of glomeruli), published in 1977.1 The trajectory of renal function in patients who have had lithium treatment discontinued
-
Repeated infusions of ketamine for treatment-resistant bipolar depression in real-world practice Bipolar Disord. (IF 5.4) Pub Date : 2023-08-06 Yanling Zhou, Xiaoyu Chen, Yuping Ning
CONFLICT OF INTEREST STATEMENT I declare no competing interests.
-
The impact of body mass index on the clinical features of bipolar disorder: A STEP-BD study Bipolar Disord. (IF 5.4) Pub Date : 2023-08-03 Bashkim Kadriu, Zhi-De Deng, Christoph Kraus, Jenessa N. Johnston, Adam Fijtman, Ioline D. Henter, Siegfried Kasper, Carlos A. Zarate
The effects of body mass index (BMI) on the core symptoms of bipolar disorder (BD) and its implications for disease trajectory are largely unexplored.
-
Topiramate use in a pediatric patient with comorbid bipolar disorder and trichotillomania: A 3-year follow-up Bipolar Disord. (IF 5.4) Pub Date : 2023-08-02 Ting Yang, Xiaolin Liang, Xiuhua Wu, Tong Li, Youzhen Lin, Zhaoyu Gan
Trichotillomania (TTM) is an intractable and chronic mental disorder that causes significant distress or functional impairments in various life domains. Most individuals with trichotillomania have other comorbid diagnoses. Bipolar disorder (BD) is one of the most common comorbid conditions. Up to date, no FDA-approved drugs for TTM are available, not to mention children and adolescent patients with
-
Unheard voices: The sexual challenges of families of patients with bipolar disorder: A qualitative content analysis Bipolar Disord. (IF 5.4) Pub Date : 2023-07-31 Safura Yaghmaei, Hassan Babamohamadi, Farshid Shamsaei, Ali Asghar Ghods
The aim of this study was to explore the voices of the family members of Bipolar Disorder (BD) patients about the challenges ahead of them.
-
Functioning in older adults with bipolar disorder: A report on recommendations by the International Society of bipolar disorder (ISBD) older adults with bipolar disorder (OABD) task force Bipolar Disord. (IF 5.4) Pub Date : 2023-07-26 Laura Montejo, Melis Orhan, Peijun Chen, Lisa T. Eyler, Ariel Gildengers, Anabel Martinez-Aran, Paula Villela Nunes, Andrew T. Olagunju, Regan Patrick, Eduard Vieta, Annemiek Dols, Esther Jimenez
Despite the importance of psychosocial functioning impairment in Bipolar Disorder (BD), its role among Older Adults with BD (OABD) is not well known. The development of guidelines for the assessment of psychosocial functioning helps to facilitate a better understanding of OABD and can lead to better tailored interventions to improve the clinical outcomes of this population.
-
Patterns of pharmacotherapy for bipolar disorder: A GBC survey Bipolar Disord. (IF 5.4) Pub Date : 2023-07-18 Balwinder Singh, Anastasia K. Yocum, Rebecca Strawbridge, Katherine E. Burdick, Caitlin E. Millett, Amy T. Peters, Sarah H. Sperry, Giovanna Fico, Eduard Vieta, Norma Verdolini, Ophelia Godin, Marion Leboyer, Bruno Etain, Ivy F. Tso, Brandon J. Coombes, Melvin G. McInnis, Andrew A. Nierenberg, Allan H. Young, Melanie M. Ashton, Michael Berk, Lana J. Williams, Kamyar Keramatian, Lakshmi N. Yatham, Bronwyn
To understand treatment practices for bipolar disorders (BD), this study leveraged the Global Bipolar Cohort collaborative network to investigate pharmacotherapeutic treatment patterns in multiple cohorts of well-characterized individuals with BD in North America, Europe, and Australia.
-
The diagnosis of bipolar disorder in children and adolescents: Past, present and future Bipolar Disord. (IF 5.4) Pub Date : 2023-07-11 Gin S. Malhi, Maedeh Jadidi, Erica Bell
This article examines the ongoing debate concerning the diagnosis of bipolar disorder in children and adolescents. This contentious issue has generated robust discussion over the past two decades without consensus, and as such the true prevalence of so-called paediatric bipolar disorder (PBD) remains unknown. In this article we offer a solution to break this deadlock.
-
Barriers to and facilitators of success for early and Mid-Career professionals focused on bipolar disorder: A global needs survey by the International Society for Bipolar Disorders Bipolar Disord. (IF 5.4) Pub Date : 2023-06-30 Sarah H. Sperry, Katie M. Douglas, Olivia M. Dean, Gabriel R. Fries, Fabiano A. Gomes, Georgina M. Hosang, Emma Morton, Bronya Sandorffy, Tamsyn E. Van Rheenen, Ni Xu, Rebekah S. Huber
The International Society for Bipolar Disorders created the Early Mid-Career Committee (EMCC) to support career development of the next generation of researchers and clinicians specializing in bipolar disorder (BD). To develop new infrastructure and initiatives, the EMCC completed a Needs Survey of the current limitations and gaps that restrict recruitment and retention of researchers and clinicians
-
Long-term course of cognitive functioning in bipolar disorder: A ten-year follow-up study Bipolar Disord. (IF 5.4) Pub Date : 2023-06-25 Camilla Bärthel Flaaten, Ingrid Melle, Thomas Bjella, Magnus Johan Engen, Gina Åsbø, Kristin Fjelnseth Wold, Line Widing, Erlend Gardsjord, Merete Glenne Øie, Siv Hege Lyngstad, Beathe Haatveit, Carmen Simonsen, Torill Ueland
Cognitive impairments are common in bipolar disorder (BD), but the long-term course remains understudied. Longitudinal data on cognitive functioning from the start of the first treatment could help clarify pathophysiological processes that shape the illness outcome. We here aim to investigate the 10-year cognitive course in BD compared to healthy controls (HC) and the effects of clinical symptoms on
-
KIOS: A smartphone app for self-monitoring for patients with bipolar disorder Bipolar Disord. (IF 5.4) Pub Date : 2023-06-20 Mehak Pahwa, Susan L. McElroy, Richard Priesmeyer, Gregg Siegel, Phyllis Siegel, Sharon Nuss, Charles L. Bowden, Rif S. El-Mallakh
This study examined the use of a self-monitoring/self-management smartphone application (app) for patients with bipolar disorder. The app was specifically designed with patient-centered computational software system based on concepts from nonlinear systems (chaos) theory.
-
Ketamine infusions for treatment-resistant bipolar depression: Commentary Bipolar Disord. (IF 5.4) Pub Date : 2023-06-16 Gustavo H. Vázquez, Ross J. Baldessarini
The recent report by Fancy and colleagues 1 on their experience with R,S-ketamine infusions for treatment-resistant depression in bipolar disorder (BD) patients is timely and encouraging in addressing treatment for BD II (BD2) and BD1 patients. Their findings add to emerging evidence that ketamine is effective in depression, including otherwise treatment-resistant depression in BD and major depressive
-
Emerging psychopathology and clinical staging in adolescent offspring of parents with bipolar disorder or schizophrenia—A longitudinal study Bipolar Disord. (IF 5.4) Pub Date : 2023-06-16 Nikita Setiaman, Esther Mesman, Neeltje van Haren, Manon Hillegers
Offspring of parents with bipolar disorder (BDo) and schizophrenia (SZo) are at increased risk for these disorders and general psychopathology. Little is known about their (dis)similarities in risk and developmental trajectories during adolescence. A clinical staging approach may help define the developmental course of illness.
-
Non-24-h sleep–wake rhythm disorder in a sighted individual with bipolar disorder Bipolar Disord. (IF 5.4) Pub Date : 2023-06-15 Jonathan S. Emens, David Kagan, Samuel Warshaw, Zoey Jopling, Muneer Rizvydeen, Anastasia K. Yocum, Melvin G. McInnis, Helen J. Burgess
CONFLICT OF INTEREST STATEMENT HJB is a consultant for Natrol, LLC and F. Hoffmann-La Roche Ltd. JSE has served as an expert witness in legal cases, including those involving Teva Pharmaceuticals USA, Inc., Apotex, Inc., Apotex Corp., MSN Pharmaceuticals, Inc. and MSN Laboratories Pvt. Ltd. All other authors report no financial or nonfinancial interests to disclose.
-
Progress in treatment-resistant bipolar depression using repeated ketamine infusions Bipolar Disord. (IF 5.4) Pub Date : 2023-06-13 Wim van den Brink, Jan van Amsterdam
In 2017, major depressive disorder and bipolar disorder affected approximately 163 and 45 million people, respectively. Bipolar disorder (BD) is a mental disorder with high morbidity and the highest lifetime risk of suicide. Most patients with BD suffer from depression during an important part of their lifespan. Another feature of BD is its high rate of treatment resistance, which is higher than that
-
The network structure of mania symptoms differs between people with and without binge eating Bipolar Disord. (IF 5.4) Pub Date : 2023-06-12 Helena L. Davies, Alicia J. Peel, Jessica Mundy, Dina Monssen, Saakshi Kakar, Molly R. Davies, Brett N. Adey, Chérie Armour, Gursharan Kalsi, Yuhao Lin, Ian Marsh, Henry C. Rogers, James T. R. Walters, Moritz Herle, Kiran Glen, Chelsea Mika Malouf, Emily J. Kelly, Thalia C. Eley, Janet Treasure, Gerome Breen, Christopher Hübel
People with bipolar disorder who also report binge eating have increased psychopathology and greater impairment than those without binge eating. Whether this co-occurrence is related to binge eating as a symptom or presents differently across full-syndrome eating disorders with binge eating is unclear.